Electra Therapeutics sets terms for $347M Nasdaq IPO under ticker ETRA
Resolved · corporate · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-20. Check what remains unresolved below before relying on it.
What does this change in the investment case for Electra Therapeutics?
New clinical biotech issuance prices public equity liquidity conditions and institutional risk appetite for late-stage antibody pipelines.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factElectra Therapeutics filed terms to price 21.7 million shares between $14 and $16 per share on the Nasdaq under the ticker ETRA. |
| What else was confirmed? | Reported factThe initial public offering targets gross proceeds of up to $347 million. |
| Does the valuation support acting? | Interpretation3 stored valuation assumptions for ETRA; the latest is dated 2026-09-18. |
| What would change the assessment? | UnknownFinal ETRA IPO Pricing and First-Day Trading Range — Check final deal pricing relative to the $14-$16 marketing range. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Electra Therapeutics filed terms to price 21.7 million shares between $14 and $16 per share on the Nasdaq under the ticker ETRA.
- · The initial public offering targets gross proceeds of up to $347 million.
- · Proceeds will be allocated to advance lead clinical candidate ipsoprubart through its SURPASS registration trial for secondary haemophagocytic lymphohistiocytosis.
Public research record
Research framework · page evidenceCompleted event assessment
primary market pricing and clinical pipeline capital funding
| Type | Claim | Scope |
|---|---|---|
| Assumption | Electra Therapeutics filed terms to price 21.7 million shares between $14 and $16 per share on the Nasdaq under the ticker ETRA. | 2026-09-20 |
| Interpretation | primary market pricing and clinical pipeline capital funding | ETRA |
Countercase, invalidators, and sources
Strong institutional order book prices ETRA at or above the upper $16 band, indicating healthy ECM risk appetite.
- · Final ETRA IPO Pricing and First-Day Trading Range — Check final deal pricing relative to the $14-$16 marketing range.
- Kinzey Capital Management: Electra Sets Nasdaq IPO Terms · 2026-09-19
What remains unresolved
- Base path
- ETRA prices within the $14-$16 range with proceeds fully funding the SURPASS trial through primary readouts.
- Adverse path
- Weak primary demand forces a downsized deal below the $14 floor, reflecting cautious biotech risk sentiment.
- Supportive path
- Strong institutional order book prices ETRA at or above the upper $16 band, indicating healthy ECM risk appetite.
- · Final ETRA IPO Pricing and First-Day Trading Range — Check final deal pricing relative to the $14-$16 marketing range.this week
Evidence
- Kinzey Capital Management: Electra Sets Nasdaq IPO Terms2026-09-19
“Electra Therapeutics is pricing 21.7 million shares at $14-$16 each on Nasdaq under ticker ETRA, targeting up to $347 million to advance ipsoprubart through its SURPASS registration trial.”
Supports: Electra Therapeutics pricing 21.7M shares at $14-$16 targeting up to $347M.